Effects of Statins on Cardiorenal Syndrome
Author(s) -
Shusuke Yagi,
Kenichi Aihara,
Yasumasa Ikeda,
Masashi Akaike,
Masataka Sata,
Toshio Matsumoto
Publication year - 2012
Publication title -
international journal of vascular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.411
H-Index - 27
eISSN - 2090-2832
pISSN - 2090-2824
DOI - 10.1155/2012/162545
Subject(s) - medicine , cardiorenal syndrome , endothelial dysfunction , oxidative stress , nitric oxide , heart failure , disease , inflammation , coronary artery disease , kidney disease , pharmacology , cardiology
Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom